Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Zehentmayr, Franz, Feurstein, Petra, Ruznic, Elvis, Langer, Brigitte, Grambozov, Brane, Klebermass, Marisa, Hüpfel, Herbert, Feichtinger, Johann, Minasch, Danijela, Heilmann, Martin, Breitfelder, Barbara, Steffal, Claudia, Gastinger-Grass, Gisela, Kirchhammer, Karoline, Kazil, Margit, Stranzl, Heidi, Dieckmann, Karin
Published in Radiotherapy and oncology (01.07.2024)
Published in Radiotherapy and oncology (01.07.2024)
Get full text
Journal Article